The relationship between changes in health behaviour and initiation of lipid-lowering and antihypertensive medications in individuals at high risk of ischaemic heart disease by unknown
Hempler et al. BMC Public Health 2012, 12:626
http://www.biomedcentral.com/1471-2458/12/626RESEARCH ARTICLE Open AccessThe relationship between changes in health
behaviour and initiation of lipid-lowering and
antihypertensive medications in individuals at
high risk of ischaemic heart disease
Nana Folmann Hempler1*, Allan Krasnik1, Charlotta Pisinger2 and Torben Jørgensen2,3,4Abstract
Background: It has been hypothesised that health conscious individuals tend to take better care of themselves by
greater adherence to preventive medications. We examined, whether long-term changes in dietary habits and
physical activity were associated with initiation of lipid-lowering and antihypertensive medications.
Methods: The study population consisted of two subsamples from the population-based cohort Inter99 study
(1999-2006) in Copenhagen, Denmark: one with systolic blood pressure > 140 mmHg (N = 557) and one with total
cholesterol > 7 mmol/L (N = 314). At a health examination, individuals completed a questionnaire about health
behaviour and had their blood pressure and cholesterol measured at baseline and after five years. Data on
medications were obtained through linkage to the Registry of Medical Product Statistics.
Results: Positive changes in physical activity (odds ratio =3.50; 95% CI 1.23-7.54) and in dietary habits
(odds ratio = 2.08; 95% CI 1.03-4.21) were associated with an increased initiation of lipid-lowering medications. With
respect to antihypertensives, no association was observed in terms of physical activity, but for diet, a positive trend
in terms of initiation was observed among those with positive changes in dietary habits (odds ratio = 1.58; 95%
CI 0.96-2.59).
Conclusion: Generally, we observed health conscious behaviour in terms of increased initiation of preventive
medications among those who reported positive changes in health behaviour. This study therefore suggests that
more attention should be given to identifying individuals and groups, who are less health conscious and thereby
less likely to engage in either preventive medications or changes in health behaviours.Background
Non-pharmacological treatment, in terms of physical ac-
tivity, dietary habits and smoking cessation, has been
shown to have a beneficial effect on biological cardiovas-
cular disease (CVD) risk factors. Physical activity is
known to modify well-known CVD risk factors, such as,
hypertension, dyslipidemia, abdominal and general obes-
ity [1-5]. Also, individual dietary interventions in pri-
mary prevention have shown moderate effects in
relation to cardiovascular risk factors, such as, blood
pressure, total cholesterol, LDL cholesterol stemming* Correspondence: nfhr@steno.dk
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reproduction in any medium, provided the orfrom dietary changes in terms of lower salt and fat,
higher fibre and fruit and vegetable consumption [6-9].
Furthermore, studies have shown that quitting smoking
reduces the risk of acute myocardial infarction [10,11].
Regarding pharmacological treatment, there have been
well-reasoned and balanced recommendations for the
use of statins for individuals, who have an elevated risk
of cardiovascular events [12-14]. Furthermore, blood-
pressure lowering drugs reduce the risk of coronary
heart disease (CHD) events and stroke, also in indivi-
duals with no previous history of cardiovascular disease
[15]. There is also evidence that users of medications for
hypertension and hypercholesterolemia may benefit
from health behaviour changes such as improved diet,
quitting smoking and exercise, particularly in the settingal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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from 2007, recommended that the general practitioner
should motivate people at high risk of CVD (10-year
absolute risk of CVD death≥5%), and with no pre-existing
CVD, to pursue health behaviour changes within 3 months,
before considering pharmacological treatment [17]. Only in
terms of a very high risk (10-year absolute risk of CVD
death≥10%), the general practitioner should not hesitate to
initiate pharmacological treatment.
Several observational studies have reported that indivi-
duals who initiate and adhere to preventive therapy such
as statin use are likely to be more health conscious, the
so-called healthy adherer effect [18-21]. ‘Healthy adherer
patients’ are more likely to see their doctors on a regular
basis, exercise, have healthier diets, stop smoking, adhere
to treatment and avoid risky behaviours.
In the present study, we investigated a possible healthy
adherer effect among individuals with an elevated risk of
ischaemic heart disease (IHD) in terms of high blood
pressure and high total cholesterol level. We hypothe-
sised that individuals who were able to change their
health behaviours, also were more likely to initiate
treatment with lipid-lowering medications and blood
pressure-lowering medications, rather than substituting
medications with behavioural change. To explore this,
we examined whether long-term changes in dietary
habits and physical activity were associated with initi-
ation of preventive medications. We conducted the study
by using two subsamples from the population-based
cohort from the Inter99 study.
Methods
Study population
The study population comprised of two subsamples of par-
ticipants from the Inter99 study, which is a population-
based randomised controlled trial, investigating the effect
of non-pharmacological intervention on cardiovascular
disease [22]. The study was performed at the Research
Centre for Prevention and Health, Denmark, approved by
the Copenhagen County Ethical Committee (KA 98155)
and registered in the Clinical Trials.gov (NCT00289237).
The Inter99 study was initiated in 1999 with a sub-
sequent five-year follow-up. The study population
comprised all individuals born in 1939-40, 1944-45,
1949-50, 1554-55, 1959-60, 1964-65, 1969-70 and liv-
ing in 11 municipalities in the southern part of Co-
penhagen County, and who were identified in the
Civil Registration System. The initial entire study
population consisted of 61,301 participants and was
pre-randomised into three groups: a high intervention
group (Group A, N = 11,708), a low intensity inter-
vention group (Group B, N = 1,308) and a control
group (N = 48,285). The inclusion criteria for the
study population in the present article were: (1)randomised to group A; (2) information on dietary habits
and physical activity at baseline and five-year follow-up; (3)
high blood pressure (>140 mmHg) (N=557) or high total
cholesterol (>7 mmol/L) (N=314) measured at baseline.
The intervention
The baseline examination took place between November
1999 and January 2001. The participants were invited for
an initial health examination and their risk of ischemic
heart disease was assessed at baseline. Using the
Copenhagen Risk Score, the 10-year absolute risk of
IHD was calculated (mean of sex, age, heredity, former
IHD, diabetes, height, weight, smoking habits, choles-
terol and blood pressure) by the computer program
“PRECARDW” [23]. At baseline, 52% of the initially
invited individuals in group A, corresponding to 6,091
men and women, participated in the baseline examin-
ation. At baseline, all participants at risk received a life-
style consultation encouraging them to healthy
behaviour (focusing on smoking, diet, physical activity
and reduction in alcohol consumption). Participants in
group A were offered group-based counselling in rela-
tion to smoking cessation and diet/physical activity, but
participation was relatively low at baseline, and adher-
ence was poor. All participants were re-invited after
one-, three- and five years. At five-year follow-up, the
health examination programme was repeated. Further-
more, all participants with high blood pressure, choles-
terol or glucose received a print-out of the results for
their general practitioner and were recommended to
contact him/her.
Assessment of dependent variables
The Registry of Medical Product Statistics contains in-
formation on all outpatient prescriptions in Denmark
using the Anatomical Therapeutic Chemical Classifica-
tion System (ATC codes). By linking survey data with
registry data using Danish unique personal identification
numbers, we identified data on prescriptions related to
lipid-lowering (code C10A and C10B) and antihyperten-
sive medications (code C02, C03, C7, C8, C09). We used
the 2007 version of the ATC/DDD classification. Initi-
ation was defined as a least one redeemed prescription
at a pharmacy in the period from baseline participation
to the end of the 5-year follow-up. Participants who
reported using the abovementioned medications at base-
line were excluded from the analyses.
Health behaviour
Information on physical activity and dietary habits was
obtained by questionnaire. Total physical activity was
calculated on the basis of two questions, on commuting
physical activity and leisure time physical activity [24].
The variable was calculated by summing responses to
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week using a five day working week) and leisure time
physical activity (converted into minutes per week).
Physical activity was defined as: decreased/unchanged
level and increased level. Change in dietary intake
(nine-class variable) was measured by a dietary quality
score (intake of fish, vegetables, fruit and fat) using a self-
administrated 52-item food questionnaire (reference pe-
riod: the last week). The questionnaire had been vali-
dated using a 28-day diet history and biomarkers as
reference methods [25]. The nine-class variable was
dichotomised into two groups: healthier and unchanged/
more unhealthy. None of the participants in this study
population received a maximum score of 9 (the healthi-
est) at baseline. Particularly, the groups that were more
unhealthy or had decreased values at follow-up were
relatively small, and therefore both health behaviour vari-
ables were dichotomised, due to small sample size.
Other covariates
Information on age and sex was taken from the Civil
Registration System. From the Integrated Database for
Labour Market Research at Statistics Denmark, informa-
tion on educational attainment at baseline was obtained.
Educational attainment was dichotomised into “high”
(at least secondary education) and “low” (primary educa-
tion only). Education is likely to be a good proxy for
income level, as expenditures for medication require co-
payments, while visits to the general practitioners are free
of charge in Denmark. Information on contacts with gen-
eral practitioners was obtained by linking to the National
Health Insurance Service Registry. At the health examin-
ation, participants provided fasting blood samples for as-
sessment of total cholesterol. Total cholesterol was
measured by enzymatic procedures (Boeringer Mannhein,
Germany).Blood pressure (BP) was measured twice with a
mercury sphygmomanometer after 5 min of rest in a lying
position. Height was measured without shoes to the near-
est cm, weight was measured without shoes and overcoat
to the nearest 0.1 kg and body mass index (BMI) was cal-
culated. Risk of ischemic heart disease was assessed by
using the “Copenhagen Risk Score” [23]. Smoking habits
at baseline were assessed by answers to self-report ques-
tions at baseline.
Statistical analysis
Data were analysed using SAS statistical software, ver-
sion 9.2 (SAS Institute., Cary, NC, USA).
The associations between initiation of preventive med-
ications and changes in health behaviour were explored
by logistic regression models. We excluded those with
diabetes, as guidelines for patients with diabetes differ
from those without diabetes. Regarding analyses for phys-
ical activity, those who reported low physical activity atbaseline due to illness or handicap were excluded (N= 14).
We examined three models of the relationship between
change in health behaviour or initiation of lipid-lowering
and antihypertensive medications. In model 1, we in-
cluded age, sex and baseline values for physical activity
(in analyses of change in physical activity) or dietary
habits (in analyses of change in dietary habits). In model
2, we included covariates of health behaviour and educa-
tional level, and in model 3, we adjusted for risk score,
BMI and in models regarding lipid-lowering medications,
we adjusted for cholesterol at baseline, and in models
regarding antihypertensives were adjusted for blood pres-
sure level. As a model control, we carried out Hosmer
and Lemeshow goodness-of-fit tests for the logistic re-
gression models. Linearity of age, cholesterol and blood
pressure were tested, and when needed, we squared the
number, or raised it to the third power. We tested plaus-
ible interaction terms between the primary explanatory
variable and sex and education.Results
Of the baseline participants in this study, about 62% in
both subsamples returned for a five-year follow-up dur-
ing 2004-2006 (Table 1). Compared with responders,
non-responders in the sample with high blood pressure
comprised more women (47.0%), daily smokers (36.3%),
diabetics (4.2%), persons with primary education only
(29.5%) and individuals with alcohol consumptions above
recommended levels (25.6%). Non-respondents in the
sample with high total cholesterol comprised more
women (51.5%), individuals with more than primary edu-
cation (40.3%), daily smokers (56.6%) and 30-35 year-
olds (7.1%).
For individuals who reported an increase in physical
activity at five-year follow-up, we observed a higher per-
centage of new users of lipid-lowering medications
(p = 0.0117) and antihypertensives (p = 0.4477) compared
with those with a decreased or unchanged level (Figure 1).
With respect to diet, we also observed a higher per-
centage of new users of lipid-lowering medications
(p = 0.0379) and antihypertensives (p = 0.0092) among
those with positive health behaviour changes, compared
with those with unchanged/unhealthier diet (Figure 1).Initiation of antihypertensive medications
In multivariate analyses, positive changes in physical ac-
tivity were not associated with initiation of antihyper-
tensives (Table 2), which was also the case in the fully
adjusted model (model 3). Regarding dietary habits, po-
sitive changes were significantly associated with increased
initiation of antihypertensives (model 1 and model 2).
When we included risk score, blood pressure level and
BMI in model 3, the association between positive changes
Table 1 Socio-demographic, health behaviour and







(n = 557) (n = 314)
Sex
Men 320 (57.5%) 187 (59.6%)
Women 237 (42.5%) 127 (40.4%)
Age group (years)
30-35 17 (3.1%) 13 (4.1%)
40-55 266 (47.7%) 166 (52.9%)
55-60 274 (49.2%) 135 (43.0%)
Educational level
More than primary education 421 (75.6%) 66 (21.0%)
Primary education only 131 (23.5%) 248 (79.0%)
Missing 5 (0.9%)
Diabetes
Positive test 9 (1.6%) 3 (1.0%)
Smoking status
Daily 136 (24.4%) 107 (34.1%)
Occasional 19 (3.4%) 11 (3.5%)
Ex-smoker 172 (30.9%) 78 (24.8%)
Never smoked 228 (40.9%) 118 (37.6%)
Missing 2 (0.4%)
Alcohol
Abstinent 50 (9.0%) 19 (6.0%)
Within recommendations 385 (69.1%) 227 (72.3%)
Above recommendations 103 (18.5%) 64 (20.4)
Missing 19 (3.4%) 4 (1.3%)
Physical activity (minutes per week)
0-112.5 59 (10.6%) 31 (9.9%)
142.5-225 122 (21.9%) 79 (25.2%)
255-420 263 (497.2%) 145 (46.2%)
450-720 74 (13.3%) 31 (9.9%)
Missing 39 (7.0%) 28 (8.9%)
Dietary habits
Unhealthy dietary habit 88 (15.8%) 44 (14.0%)
Average dietary habits 371 (66.7%) 215 (68.5%)
Healthy dietary habits 83 (14.9%) 42 (13.4%)
Missing 15 (2.7%) 13 (4.1%)
Body mass index, kg/m2
Mean 28.4 27.0




Table 1 Socio-demographic, health behaviour and
biological measurements in the study population
(Continued)
At least one contact with GP
Within 1 year after baseline 99.6% 100%
a: Participants who report current use of antihypertensives (n = 128) were
excluded.
b: No participants reported use of lipid-lowering medications within the last
few weeks.
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was no longer statistically significant (model 3).
Initiation of lipid-lowering medications
With respect to physical activity, positive changes were
significantly associated with an increased initiation of
lipid-lowering medications (Table 3, model 1). The asso-
ciation remained significant when the models were ad-
justed for educational level, health behaviour, risk score,
cholesterol and BMI. Regarding dietary habits, initiation
of lipid-lowering medications was more frequent in the
group that reported positive changes, compared with
those with unchanged/more unhealthy dietary habits, but
estimates were not significant (model 1). After adjusting
for risk score, cholesterol level and BMI, the association
was statistically significant (model 3).
Additional analyses
We repeated analyses for model 3 and adjusted for par-
ticipation/nonparticipation in a diet and exercise group-
based counseling programme. A similar pattern was
found for the four outcomes (data not shown). We also
compared initiation of medications between the partici-
pants and the drop-outs, and adjusted for all baseline
covariates. Regarding initiation of lipid-lowering medica-
tions (odds ratio = 1.02; 95% CI 0.56-1.31) and antihyper-
tensives (odds ratio = 1.01; 95% CI 0.69-1.48), no notable
differences were observed between the groups.
Discussion
The main finding of this study was that positive changes
in dietary habits were associated with increased initi-
ation of lipid-lowering and antihypertensive medications.
Furthermore, participants, who reported an increase in
terms of physical activity were more likely to initiate
treatment with lipid-lowering medications; however, in
terms of antihypertensives, no association was observed.
Some associations may be non-significant due to type 2
errors resulting from the relatively small sample size.
Our hypothesis that people who were able to change
their health behaviour also would tend to take better
care of themselves, by greater adherence to preventive
medications, was therefore supported to some extent.





















Percentage of new users (%)
Figure 1 The relationship between changes in health behaviour and initiation of antihypertensives and lipid-lowering medications at
5-year follow-up.
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terol ought to initiate treatment with preventive medica-
tions and/or change in health behaviour, but to shed
light on a possible health conscious behaviour and thereby
also lack of health consciousness in other individuals.
A study by Brookhart et al. reported that patients who
adhered to statin therapy underwent a variety of cancer
screening tests, received influenza and pneumococcal
vaccinations, compared with those who were less adher-
ent [26]. In another study by Majumdar et al., focusing
on patients admitted to hospital with community
acquired pneumonia, statin users were more likely to be
former smokers and have up-to-date immunizations
for pneumococcus and influenza [18]. Furthermore,
Dormuth et al. reported that patients with good adher-
ence to therapy with statins were less likely to be
involved in motor vehicle or work place accidents re-
quiring medical attention than less adherent patients
[20]. Although the studies differ in terms of design,Table 2 Effect of five-year change in health behaviour on init





Increase 87 1.00 (0.54-1.84)
Dietary habits
Unchanged/more unhealthy 189 1
Healthier 219 1.59 (1.03-1.44)
Model 1: Age, sex, baseline values for physical activity/dietary habits.
Model 2: +Education, health behaviour (smoking status, alcohol, diet/physical activi
Model 3: +Risk score, blood pressure level, BMI.
a: Participants who report use of antihypertensives (baseline, n = 128) were excludeoutcome measure and definition of adherence, they all
suggest a healthy adherer or healthy user effect.
Medical treatment with preventive medications is like-
ly to be determined by system-, provider, as well as
patient-level factors, and the factors also interact [27]. In
this study, it might be speculated that it was the most
health conscious participants who consulted their gen-
eral practitioner regarding their increased risk of IHD.
The most health conscious individuals may be more
open-minded regarding preventive medications and may
even demand such treatment. Nevertheless, health con-
sciousness in itself does not lead to the prescribing of
medications. In Denmark, primary prevention of cardio-
vascular disease is often handled by the general prac-
titioners. Almost all participants in our study visited
their general practitioner within one year after baseline
(Table 1), but it remains unknown, how many actually
consulted their general practitioners due to their
increased risk of IHD and/or motivation for healthiation of antihypertensive medicationsa






1.03 (0.55-1.93) 1.09 (0.55-2.15)
1 1
1.64 (1.03-2.60) 1.58 (0.96-2.59)
ty).
d.
Table 3 Effect of five-year change in health behaviour on initiation of lipid-lowering medications








Unchanged/decrease 193 1 1 1
Increase 71 2.96 (1.34-6.53) 3.01 (1.31-6.90) 3.05 (1.23-7.54)
Dietary habits
Unchanged/more unhealthy 149 1 1 1
Healthier 143 1.61 (0.90-2.86) 1.85 (0.97-3.53) 2.08 (1.03-4.21)
Model 1: Age, sex, baseline values for physical activity/dietary habits.
Model 2: +Education, health behaviour (smoking status, alcohol, diet/physical activity).
Model 3: +Risk score, cholesterol level, BMI.
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does not provide information about diagnoses related
to contacts.
On the other hand, participation in a non-
pharmacological intervention (as with the Inter99 study)
might have affected the general practitioners’ decisions
regarding treatment, in terms of a hesitation towards ini-
tiating treatment. Generally, the prescribing of prevent-
ive medications has been much debated, also among
general practitioners. A recent Cochrane review, re-
ported a stronger effect of statins on overall mortality
than observed in previous meta-analyses [14], but at the
same time the authors did not support the widespread
use of statins in individuals without a previous history of
heart disease, due to high costs and risks associated with
side effects [28]. Another fact is that Danish national
guidelines from 1998 and 2002 were less likely to recom-
mend pharmacological treatment as primary treatment
for IHD, as was the case in the 2007 guideline. Also,
general practitioners were very reluctant to initiate treat-
ment with statins, as the price was very high and regula-
tions on subsidies were very complicated in the first
years of the study. This is likely to explain the relatively
low prevalence of users.
Generally, participants with unchanged/negative
changes in health behaviour were less likely to initiate
treatment with preventive medications, but this was not
the case for antihypertensives and physical activity, where
no healthy adherer affect was observed. One explan-
ation for this finding might be that physicians have a
tendency to prescribe medications to patients, who are
most likely to benefit from them [27], for example as a
result of unhealthy behaviours or poorer health status.
However, we tried to take this into consideration, by
excluding those who reported a decrease in physical ac-
tivity due to illness/handicap and by adjusting for blood
pressure/cholesterol and risk score. Differences in health
status did appear to have some effect, as some associationswere strengthened by the inclusion of the above men-
tioned variables.
The generalisability of our study should be made care-
fully, as our study population is relatively young, re-
ceived lifestyle intervention and were referred to their
general practitioners. The strengths of this study are the
follow-up design and the fact that we were able to link
data to the Danish National Prescription Registry of high
validity [29]. Our study also has limitations. The rela-
tively low participation rate at baseline might cause
some selection bias, because group A had lower BMI
than the general population (group C), but poorer life-
style [22]. Nevertheless, the intervention groups have
been found to be representative for the general popula-
tion (group c) with regard to former admissions for all
causes, IHD, CVD and diabetes [22]. Another thing to
keep in mind is the selection in drop-out at five-year fol-
low-up. It is likely that it was the most health conscious
individuals who returned at follow-up. However, we con-
sider this less relevant, as we investigate associations for
participants with complete data. Furthermore, we cannot
exclude the risk of residual confounding due to broad
categories of dietary habits and physical activity. A weak-
ness is also that health behaviour data are self-report,
which involves a risk of bias and misclassification. It
cannot be ruled out that some participants may have
reported too positive changes in health behaviour; how-
ever, this would lead to underestimated associations be-
tween changes in health behaviour and initiation of
medications. Previous cardiovascular events might also
cause a selection and therefore affect the findings; but,
due to the relatively young population, and the fact that
we excluded those with existing use of medications and
diabetes, we consider this less relevant. We might have
underestimated the associations, as participants who
were the healthiest at baseline may have difficulties in
increasing their scores; the so-called ceiling effect. Fi-
nally, we did not consider subgroups of medications,
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comorbidity, such as with migraines, might require
antihypertensives.
Conclusion
The study partially supports the hypothesis of health
conscious behaviour in terms of increased initiation of
preventive medications among those who experienced
positive changes in health behaviour. This fact implies
that studies that examine the effect of lipid-lowering and
antihypertensive medications might consider the healthy
adherer effect in terms of a potential bias. From a public
health perspective, our study suggest that more attention
should be given to identifying individuals and groups,
who are less health conscious and thereby less likely to
engage in either preventive medication or changes in
health behaviour. Further research is needed to under-
stand the complex interactions between healthy behav-
iour and preventive medication and the role of individual
perceptions of health, health behaviour and medication.
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